G. Verheijden

A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA

R. Ubink, M. Wuhrer, W. Dokter, 2016, mAbs.

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

R. Ubink, M. Eppink, P. Beusker, 2014, Molecular Cancer Therapeutics.

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

R. Ubink, P. Beusker, W. Dokter, 2015, Molecular Cancer Therapeutics.

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.

R. Ubink, P. Beusker, W. Dokter, 2015, Molecular pharmaceutics.

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

R. Ubink, T. K. van den Berg, M. Paradé, 2023, Journal for ImmunoTherapy of Cancer.

Optimizing heterologous expression in dictyostelium: importance of 5' codon adaptation.

P. V. Haastert, G F Verheijden, M H Linskens, 2000, Nucleic acids research.